4.7 Article

N-Myc-induced metabolic rewiring creates novel therapeutic vulnerabilities in neuroblastoma

Journal

SCIENTIFIC REPORTS
Volume 10, Issue 1, Pages -

Publisher

NATURE RESEARCH
DOI: 10.1038/s41598-020-64040-1

Keywords

-

Funding

  1. German Federal Ministry of Education and Research (BMBF)
  2. graduate school 'Computational Systems Biology (CSB)' of the German Research Foundation (DFG Graduiertenkolleg) [1772]

Ask authors/readers for more resources

N-Myc is a transcription factor that is aberrantly expressed in many tumor types and is often correlated with poor patient prognosis. Recently, several lines of evidence pointed to the fact that oncogenic activation of Myc family proteins is concomitant with reprogramming of tumor cells to cope with an enhanced need for metabolites during cell growth. These adaptions are driven by the ability of Myc proteins to act as transcriptional amplifiers in a tissue-of-origin specific manner. Here, we describe the effects of N-Myc overexpression on metabolic reprogramming in neuroblastoma cells. Ectopic expression of N-Myc induced a glycolytic switch that was concomitant with enhanced sensitivity towards 2-deoxyglucose, an inhibitor of glycolysis. Moreover, global metabolic profiling revealed extensive alterations in the cellular metabolome resulting from overexpression of N-Myc. Limited supply with either of the two main carbon sources, glucose or glutamine, resulted in distinct shifts in steady-state metabolite levels and significant changes in glutathione metabolism. Interestingly, interference with glutamine-glutamate conversion preferentially blocked proliferation of N-Myc overexpressing cells, when glutamine levels were reduced. Thus, our study uncovered N-Myc induction and nutrient levels as important metabolic master switches in neuroblastoma cells and identified critical nodes that restrict tumor cell proliferation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Immunology

Case Report: Rubella Virus-Induced Cutaneous Granulomas in Two Pediatric Patients With DNA Double Strand Breakage Repair Disorders - Outcome After Hematopoietic Stem Cell Transplantation

Ulrich Baumann, Johannes H. Schulte, Jonathan P. Gross, Rita Beier, Marius Ludwig, Volker Wahn, Jorg Hofmann, Britta Maecker-Kolhoff, Martin Sauer, Petra Kaiser-Labusch, Negin Karimian, Ulrike Blume-Peytavi, Franziska Ghoreschi, Hagen Ott, Ludmila Perelygina, Christian Klemann, Oliver Blankenstein, Horst von Bernuth, Renate Krueger

Summary: We report two patients with DNA repair disorders who developed destructive skin granulomas after receiving live-attenuated rubella vaccinations. Both patients exhibited reduced naive T cells. Hematopoietic stem cell transplantation resulted in rapid resolution of skin lesions. However, one patient with severe complications died 6 months after HSCT. Newborn screening may be beneficial in preventing patients with moderate T-cell deficiencies from receiving rubella vaccine that may lead to granulomas.

FRONTIERS IN IMMUNOLOGY (2022)

Letter Hematology

Rituximab therapy after pediatric hematopoietic stem cell transplantation can cause prolonged B-cell impairment and increases the risk for infections - a retrospective matched cohort study

Michael Launspach, Dennis Temel, Emily Ohlendorf, Felix Zirngibl, Bianca Materne, Lena Oevermann, Hedwig E. Deubzer, Anton G. Henssen, Annette Kunkele, Patrick Hundsdorfer, Horst von Bernuth, Axel Pruss, Angelika Eggert, Arend von Stackelberg, Peter Lang, Johannes H. Schulte

HAEMATOLOGICA (2023)

Article Immunology

Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model

Sara Marie Ivasko, Kathleen Anders, Laura Grunewald, Michael Launspach, Anika Klaus, Silke Schwiebert, Peter Ruf, Horst Lindhofer, Holger N. N. Lode, Lena Andersch, Johannes H. H. Schulte, Angelika Eggert, Patrick Hundsdoerfer, Annette Kuenkele, Felix Zirngibl

Summary: Despite advances in treatment, relapse is still a concern for a significant number of high-risk neuroblastoma patients. Bispecific trifunctional antibodies (trAbs) have shown promising potential as a new immunotherapy for neuroblastoma. The SUREK trAb has been demonstrated to effectively kill neuroblastoma cells and enhance adaptive immune responses through binding to antigen-presenting cells. Combining trAb therapy with anti-PD-1 checkpoint blockade may further improve treatment outcomes.

FRONTIERS IN IMMUNOLOGY (2023)

Article Pediatrics

Molecular characterization of the circadian clock in paediatric leukaemia patients: a prospective study protocol

Marius Ludwig, Alireza Basti, Muege Yalcin, Johannes H. Schulte, Angela Relogio

Summary: This study aims to characterize the circadian clock in pediatric patients with acute leukemia, for the first time. By collecting saliva, blood, and bone marrow samples, the researchers will analyze the expression of core-clock genes. The findings of this study may contribute to adjusting chemotherapy timing and reducing systemic toxicities.

BMC PEDIATRICS (2023)

Article Oncology

Genomic ALK alterations in primary and relapsed neuroblastoma

Carolina Rosswog, Jana Fassunke, Angela Ernst, Birgid Schoemig-Markiefka, Sabine Merkelbach-Bruse, Christoph Bartenhagen, Maria Cartolano, Sandra Ackermann, Jessica Theissen, Mirjam Blattner-Johnson, Barbara Jones, Kathrin Schramm, Janine Altmueller, Peter Nuernberg, Monika Ortmann, Frank Berthold, Martin Peifer, Reinhard Buettner, Frank Westermann, Johannes H. Schulte, Thorsten Simon, Barbara Hero, Matthias Fischer

Summary: Genomic alterations of the ALK gene occur recurrently in neuroblastoma, with ALK mutations occurring in 10.5% of cases at diagnosis and increasing by 70% at relapse. However, the frequency of ALK amplifications does not change over the course of the disease. Regular monitoring of the genomic ALK status and evaluation of ALK-targeted treatment in intermediate-risk patients is recommended.

BRITISH JOURNAL OF CANCER (2023)

Article Hematology

Automated production of specific T cells for treatment of refractory viral infections after allogeneic stem cell transplantation

Amadeus T. Heinz, Friso G. J. Calkoen, Alexander Derbich, Lea Miltner, Christian Seitz, Michaela Doering, Christiane Braun, Daniel Atar, Michael Schumm, Florian Heubach, Anne- Marie Arendt, Ansgar Schulz, Friedhelm R. Schuster, Roland Meisel, Brigitte Strahm, Juergen Finke, Beatrice Heineking, Susanne Stetter, Gerda Silling, Daniel Stachel, Bernd Gruhn, Klaus-Michael Debatin, Juergen Foell, Johannes H. Schulte, Wilhelm Woessmann, Christine Mauz-Koerholz, Johanna Tischer, Tobias Feuchtinger, Rupert Handgretinger, Peter Lang

Summary: Therapy-resistant viral reactivations after hematopoietic stem cell transplantation can be effectively reduced by adoptive cellular therapy with virus-specific T cells. In this study, the in-house production of virus-specific T cells in a closed system was successful and showed favorable safety profile and efficacy in 26 patients.

HAEMATOLOGICA (2023)

Article Oncology

Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial

Tim Flaadt, Ruth L. Ladenstein, Martin Ebinger, Holger N. Lode, Helga Bjoerk Arnardottir, Ulrike Poetschger, Wolfgang Schwinger, Roland Meisel, Friedhelm R. Schuster, Michaela Doering, Peter F. Ambros, Manon Queudeville, Joerg Fuchs, Steven W. Warmann, Juergen Schaefer, Christian Seitz, Patrick Schlegel, Ines B. Brecht, Ursula Holzer, Tobias Feuchtinger, Thorsten Simon, Johannes H. Schulte, Angelika Eggert, Heiko-Manuel Teltschik, Toni Illhardt, Rupert Handgretinger, Peter Lang

Summary: This study investigates the use of haploidentical stem cell transplantation and the anti-GD2 antibody dinutuximab beta (DB) in treating patients with relapsed high-risk neuroblastoma (rHR-NB). The results show that DB therapy is feasible and improves the chances of cure in rHR-NB patients.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Biochemistry & Molecular Biology

Quantification of Ergot Alkaloids via Lysergic Acid Hydrazide-Development and Comparison of a Sum Parameter Screening Method

Maximilian Kuner, Jan Lisec, Tatjana Mauch, Joerg Konetzki, Hajo Haase, Matthias Koch

Summary: Ergot alkaloids are mycotoxins found in grass-derived products, and they have been recently regulated in the EU. A new sum parameter method (SPM) targeting all ergot alkaloids simultaneously was developed using lysergic acid hydrazide. The SPM showed comparable results to the established HPLC-MS/MS-based method (ESM) in evaluating food safety, while another method (LFGB) showed deviating results. The SPM is a promising alternative for screening ergot alkaloids in food.

MOLECULES (2023)

Article Multidisciplinary Sciences

SOX11 regulates SWI/SNF complex components as member of the adrenergic neuroblastoma core regulatory circuitry

Bieke Decaesteker, Amber Louwagie, Siebe Loontiens, Fanny De Vloed, Sarah-Lee Bekaert, Juliette Roels, Suzanne Vanhauwaert, Sara De Brouwer, Ellen Sanders, Alla Berezovskaya, Geertrui Denecker, Eva D'haene, Stephane Van Haver, Wouter Van Loocke, Jo Van Dorpe, David Creytens, Nadine Van Roy, Tim Pieters, Christophe Van Neste, Matthias Fischer, Pieter Van Vlierberghe, Stephen S. Roberts, Johannes Schulte, Sara Ek, Rogier Versteeg, Jan Koster, Johan van Nes, Mark Zimmerman, Katleen De Preter, Frank Speleman

Summary: SOX11 is identified as a potential epigenetic master regulator upstream of the core regulatory circuitry in adrenergic high-risk neuroblastoma.

NATURE COMMUNICATIONS (2023)

Article Immunology

Case report: HLA-haploidentical HSCT rescued with donor lymphocytes infusions in a patient with X-linked chronic granulomatous disease

Julia Scheiermann, Annette Kuenkele, Arend von Stackelberg, Angelika Eggert, Peter Lang, Felix Zirngibl, Luise Martin, Johannes Hubertus Schulte, Horst von Bernuth

Summary: Chronic granulomatous disease is a congenital immunodeficiency disorder caused by a disruption in the function of the NADPH oxidase complex. It leads to impaired respiratory burst and inadequate killing of bacteria and fungi. Allogeneic HSCT is the only available curative therapy.

FRONTIERS IN IMMUNOLOGY (2023)

Article Cell Biology

Fibroblast Activation Protein-Targeting Minibody-IRDye700DX for Ablation of the Cancer-Associated Fibroblast with Photodynamic Therapy

Esther M. M. Smeets, Daphne N. Dorst, Gerben M. Franssen, Merijn S. van Essen, Cathelijne Frielink, Martijn W. J. Stommel, Marija Trajkovic-Arsic, Phyllis F. Cheung, Jens T. Siveke, Ian Wilson, Alessandro Mascioni, Erik H. J. G. Aarntzen, Sanne A. M. van Lith

Summary: Fibroblast activation protein (FAP)-targeted photodynamic therapy shows promise in diagnosing and treating various tumors. By conjugating a FAP-binding minibody with the chelator DTPA and the photosensitizer IRDye700DX, FAP-expressing cells can be selectively recognized and killed. In vivo experiments in mice confirm the tumor-targeting ability of DTPA-700DX-MB and demonstrate its efficacy in inducing apoptosis through light exposure, suggesting the potential of FAP-targeted photodynamic therapy.

CELLS (2023)

Article Oncology

Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp

Jessica C. Hassel, Carola Berking, Andrea Forschner, Christoffer Gebhardt, Lucie Heinzerling, Friedegund Meier, Sebastian Ochsenreither, Jens Siveke, Axel Hauschild, Dirk Schadendorf

Summary: Tebentafusp is the first approved treatment option for HLA-A*02:01 metastatic uveal melanoma and has a new adverse event profile. Recommendations for its treatment, including AE management, were discussed by a national expert group. Patients in good clinical condition and with a low tumor burden are good candidates for Tebentafusp treatment.

EUROPEAN JOURNAL OF CANCER (2023)

Article Oncology

Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study

Dirk Tomsitz, Theresa Ruf, Markus Heppt, Ramon Staeger, Egle Ramelyte, Reinhard Dummer, Marlene Garzarolli, Friedegund Meier, Eileen Meier, Heike Richly, Tanja Gromke, Jens T. Siveke, Cindy Franklin, Kai-Christian Klespe, Cornelia Mauch, Teresa Kilian, Marlene Seegraeber, Bastian Schilling, Lars E. French, Carola Berking, Lucie Heinzerling

Summary: A retrospective, multicenter study was conducted to analyze the outcomes and safety of tebentafusp therapy in 78 patients with metastatic uveal melanoma (mUM). The study showed that patients treated with tebentafusp had a median progression-free survival (PFS) of 3 months and a median overall survival (OS) of 22 months. There was a higher rate of patients with elevated LDH in this cohort compared to a published Phase 3 study. Patients treated with tebentafusp following immune checkpoint inhibitor (ICI) therapy had a trend for a longer OS.

CANCERS (2023)

Article Engineering, Environmental

Levels of per- and polyfluoroalkyl substances (PFAS) in various wastewater-derived fertilizers - analytical investigations from different perspectives

Christian Vogel, Philipp Roesch, Philipp Wittwer, Christian Piechotta, Jan Lisec, Thomas Sommerfeld, Stephanie Kluge, Hannes Herzel, Thomas Huthwelker, Camelia Borca, Franz-Georg Simon

Summary: Solid wastewater-based fertilizers were screened for PFAS using the EOF sum parameter method. The results showed a wide range of EOF values in these fertilizers, and only a small part of the values could be explained by the usual screened PFAS. The study also found the presence of other fluorinated compounds in these fertilizers, which can degrade to short-chain PFAS in wastewater treatment plants, contributing to the pollution of organic fluorine in the environment.

ENVIRONMENTAL SCIENCE-ADVANCES (2023)

Article Chemistry, Analytical

Data processing made easy: standalone tool for automated calculation of isotope ratio from transient signals - IsoCor

Dariya Tukhmetova, Jan Lisec, Jochen Vogl, Bjoern Meermann

Summary: This paper introduces a data processing application called IsoCor, which can automatically calculate isotope ratios from transient signals and simplify the selection of the most suitable method. The feasibility and reliability of the application are proven through the analysis of isotopes of three elements.

JOURNAL OF ANALYTICAL ATOMIC SPECTROMETRY (2022)

No Data Available